|
The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: ---------- Angus Energy PLC - UK-focused onshore oil and gas developer - Reaches agreement to restructure its debt with Trafigura. The restructuring is expected to provide a ‘stable financial platform to support future operations and deliver long-term shareholder value.’ By consolidating and refinancing existing debt facilities, Angus Energy believes it will be better positioned to raise new capital in support of organic growth, increased production, and potential M&A activity. ‘The company is benefitting from higher oil and gas prices and continues to carefully manage its working capital position in conjunction with its lenders,’ it says. In addition, continues with its due diligence on the purchase of a group of producing assets located in the Gulf of America. ‘The board is meeting in the coming weeks to agree whether or not to proceed with the transaction,’ Angus Energy says. ---------- Cordel Group PLC - London-based transport corridor analytics platform - Expands contract working with a ‘significant’ customer based in the Middle East. This follows the successful conclusion of the initial 6-month contract announced in June 2024. Cordel has now been awarded a second phase covering around double the amount of track mileage capture and analysis, which is to be delivered over the next 6 months. Chief Executive John Davis says: ‘With considerable investment across the region, Cordel is well-positioned to play an important role in delivering leading edge digital inspection technologies.’ ---------- Avation PLC - Singapore-based commercial aircraft leasing company - Announces the signing of an eight-year lease agreement with a European [aircraft, crew, maintenance, and insurance] provider for an eight-year-old ATR 72-600 aircraft. The aircraft is scheduled to be transitioned in February 2026. Executive Chair Jeff Chatfield says the lease improves Avation’s contracted revenue and airline diversification. ---------- Colefax Group PLC - designer and distributor of furnishing fabrics and wallpapers - Announces proposed tender offer for up to 15% of its share capital. The offer is being made at the lower of 880 pence per share or 105% of the average closing mid-market price per share as derived from the London Stock Exchange Daily Official List over the five business days immediately preceding the take-up announcement date. ---------- Norman Broadbent PLC - London-based recruitment firm - Net fee incomes rises 26% to £2.9 million in the third quarter to September from £2.3 million the year prior. This takes NFI to £8.9 million for 2025 to date, up 31% from £6.8 million a year ago. Chief Executive Kevin Davidson says: ‘I am delighted to report that, despite persistent market challenges, the very positive trading performance demonstrated over the past year has continued through the third quarter.’ Adds: ‘Furthermore, new project awards have held up over the summer trading months and the value of future contracted revenue at the beginning of Q4 was in line with the position at the start of Q3. This provides great momentum for us as we push to deliver a strong close to the year.’ Davidson says: ‘We continue to look to the future with considerable optimism.’ ---------- Abingdon Health PLC - York, England-based maker of lateral flow diagnostic tests - Plans to raise £3.3 million via placing at 6 pence per share and £200,000 by way of a retail offer at the same price. The placing, to institutional and other investors, will be conducted by way of an accelerated bookbuild. Zeus Capital Ltd is acting as sole broker in relation to the placing. Proceeds will be used to accelerate expansion operations in the US, enhance working capital required in new higher revenue-generating projects including recent major contract wins and future anticipated pipeline opportunities. On completion, Abingdon Health anticipates that the company will have cash resources in excess of £4 million. ---------- Ananda Pharma PLC - London-based biopharmaceutical company that develops regulatory-approved cannabinoid medicines to treat complex, chronic conditions - Pretax loss from operations widens to £2.0 million in the six months to July 31 from £1.2 million the year prior. Revenue rises to £5,135 from just £764 but administrative expenses double to £1.6 million from £756,938. ---------- Aptamer Group PLC - York, England-based synthetic binders developer - Announces a new fee-for-service development contract valued at £112,000 with a top 10 global pharmaceutical company. This agreement represents success-based repeat business with an existing partner, focusing on the development of Optimer binders against two protein targets to support the partner’s internal biomarker research, Aptamer explains. The new contract adds to the existing visibility of £1.0 million in contract value for financial 2026, bringing the total to £1.1 million. Aptamer says it has a ‘robust’ fee-for-service pipeline of £3.3 million, after adjusting for the closure of this deal, which includes approximately £1.0 million in late-stage discussion. But does not provide formal guidance for FY26, as ‘contract timings, project completions and revenue recognition can vary significantly across quarters due to the nature of the business.’ ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
